DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**Name of Committee:** National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI SBIR Phase IIB Bridge Awards.

**Date:** December 7, 2017.
**Time:** 9:30 a.m. to 5:00 p.m.
**Agenda:** To review and evaluate grant applications.

**Place:** Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW., Washington, DC 20015.

**Contact Person:** Susan Wohler Sunnarborg, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7182, Bethesda, MD 20892, 301–827–7939, susan.sunnarborg@nih.gov.

**Catalogue of Federal Domestic Assistance Program Nos.**
- 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS

Dated: November 9, 2017.

Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–24897 Filed 11–16–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**Name of Committee:** National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting.

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; AA–1 and AA–4 Conflict Applications.

**Date:** December 11, 2017.
**Time:** 1:00 p.m. to 3:30 p.m.
**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 5635 Fishers Lane, Room 20892, 301–443–2861, marmillotp@mail.nih.gov.

**Catalogue of Federal Domestic Assistance Program Nos.**
- 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians;
- 93.272, Alcohol National Research Service Awards for Research Training;
- 93.273, Alcohol Research Programs;
- 93.891, Alcohol Research Center Grants;
- 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS


Melanie J. Pantoya,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–24896 Filed 11–16–17; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**Name of Committee:** National Cancer Institute; Notice of Closed Meeting.

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; Oct2017 Cycle 27 NExT SEP Committee Meeting.

**Date:** December 13, 2017.
**Time:** 8:30 a.m. to 4:30 p.m.
**Agenda:** To evaluate the NCI Experimental Therapeutics Program Portfolio.

**Place:** National Institutes of Health, 9000 Rockville Pike, Building 31, Wing 6, 6th Floor, Conference Room 10, Bethesda, MD 20892.

**Contact Persons:** Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Therapeutics Program Portfolio.